Mylan makes major pharma acquisition in India

NYSE-listed Mylan Laboratories to acquire 71.5% of IndiaÆs Matrix Laboratories for a maximum price of $736 million in deal in which private equity investors in Matrix Laboratories will take a stake in acquirer, Mylan.

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition